Klivira
Request demo

Automating OB/GYN GLP-1 Prior Auth for Women's Health

Klivira provides specialized automation for ob/gyn GLP-1 prior auth, streamlining approvals for medications like Ozempic, Wegovy, and Mounjaro within the unique context of women's health.

Obstetrics and gynecology practices frequently manage patients with conditions requiring GLP-1 receptor agonists, whether for type 2 diabetes or obesity. Navigating the complex, high-volume prior authorization landscape for these medications can significantly strain revenue cycle operations and delay patient care. Klivira's platform integrates seamlessly to manage these critical workflows.

The Intersection of Women's Health and GLP-1 Therapy

OB/GYN practices encounter GLP-1 prescribing for various reasons, including managing type 2 diabetes in high-risk pregnancies or addressing obesity in pre-conception counseling and fertility services. The high volume of GLP-1 PAs, coupled with payer-specific coverage variations for obesity, necessitates a specialized approach that understands the clinical nuances of women's health.

Key GLP-1 Prior Authorization Triggers in OB/GYN

  • Management of type 2 diabetes in high-risk obstetric patients (e.g., gestational diabetes with progression).
  • Obesity management for patients undergoing fertility treatments where BMI criteria apply.
  • Pre-conception counseling involving weight management and chronic disease.
  • Prescribing GLP-1s like Ozempic, Wegovy, Mounjaro, Zepbound, or Saxenda for approved indications.
  • Documentation of step therapy, BMI, and A1C for payer policy adherence.

Streamlining GLP-1 PA Workflows in OB/GYN

Klivira automates the complex GLP-1 prior authorization process by integrating directly with your EMR via SMART on FHIR. Our system identifies the indication (T2D vs. obesity), applies brand-specific PA criteria, and leverages per-payer obesity-coverage routing to ensure accurate and timely submissions. This reduces manual effort and accelerates access to critical medications.

Klivira's Indication-Aware Automation for OB/GYN

  • Indication Classification: Automatically distinguishes between type 2 diabetes and obesity indications from EMR data.
  • Payer Policy Logic: Applies per-payer obesity benefit status and brand-specific PA criteria for drugs like Ozempic or Mounjaro.
  • Documentation Automation: Pulls required clinical data—such as metformin trial history, BMI, and comorbidity status—from FHIR-enabled EMRs.
  • Specialty Pharmacy Integration: Facilitates post-approval routing to specialty pharmacies for many GLP-1 products.
  • Patient Financial Counseling: Integrates with financial counseling workflows to surface manufacturer copay programs when obesity indications are denied.

Addressing Unique OB/GYN PA Challenges

Beyond GLP-1s, OB/GYN practices face unique PA demands, including time-sensitive obstetric workflows and high payer variability for fertility services. Klivira's platform addresses these by incorporating gestational-age-aware routing and fertility-benefit-structure routing, ensuring comprehensive PA management across the women's health spectrum.

EMR and Payer Touchpoints for GLP-1 PA

  • EMR order entry for GLP-1 medications (e.g., Epic, Cerner, Athenahealth).
  • Clinical documentation templates for BMI, A1C, and comorbidity data.
  • X12 278 transactions for electronic prior authorization (ePA).
  • Payer portals for submission and status checks when ePA is not available.
  • Integration with NCPDP SCRIPT standards for pharmacy benefit PAs.

Frequently asked questions

How does Klivira handle the distinction between T2D and obesity indications for GLP-1 PAs in OB/GYN?

Klivira's platform automatically classifies the indication by extracting diagnosis codes and clinical context from your EMR. This allows for precise routing based on payer policies, which often differentiate coverage for GLP-1s prescribed for type 2 diabetes versus obesity.

What specific documentation does Klivira automate for GLP-1 prior authorizations?

Klivira automates the collection of critical documentation, including BMI, A1C levels, and evidence of step therapy (e.g., metformin trial history). This data is pulled directly from your FHIR-enabled EMR, reducing manual chart review and data entry for your PA coordinators.

How does Klivira address the rapid changes in payer coverage for GLP-1s, especially for obesity indications?

Klivira's policy engine maintains an updated database of per-payer obesity benefit statuses and brand-specific PA criteria. This ensures that submissions are always aligned with current payer requirements, adapting to the rapidly evolving coverage landscape for medications like Wegovy and Zepbound.

Can Klivira integrate GLP-1 PA workflows with other high-volume OB/GYN prior authorizations?

Yes, Klivira is designed to manage a comprehensive range of OB/GYN prior authorizations. This includes high-volume categories like fertility services, advanced maternal-fetal imaging, and major gynecologic surgeries, alongside GLP-1s, providing a unified platform for all your PA needs.

What happens if a GLP-1 prior authorization for an obesity indication is denied by the payer?

In cases where an obesity indication is denied, Klivira's workflow can integrate with patient financial counseling. The platform can surface information on manufacturer copay programs and alternative coverage paths, helping patients access their prescribed medications.

Related coverage

Other ob-gyn prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo